Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy.

NCT00148395 is registered in ClinicalTrials.gov with Aktion Bronchialkarzinom e.V. as lead sponsor.

NCT NCT00148395
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00148395 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy.
Lead sponsor
Aktion Bronchialkarzinom e.V.
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2002
Completion date
April 30, 2008
Enrollment
280
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small-cell lung carcinoma